Circulating free DNA concentration is an independent prognostic biomarker in lung cancer

European Respiratory Journal

Volumn 46, Issue 6, 2015, Pages 1773-1780

  Tissot, Claire ^a,b   Toffart, Anne Claire ^c,d   Villar, Stéphanie ^b   Souquet, Pierre Jean ^a   Merle, Patrick ^e   Moro Sibilot, Denis ^c,d   Pérol, Maurice ^f   Zavadil, Jiri ^b   Brambilla, Christian ^c,d   Olivier, Magali ^b   Couraud, Sébastien ^a,g  

^a UNIVERSITÉ DE LYON   (France)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^c UNIV GRENOBLE ALPES   (France)

^d HÔPITAL MICHALLON   (France)

^e UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^f CENTRE LÉON BÉRARD   (France)

^g UNIVERSITÉ CLAUDE BERNARD LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CIRCULATING CELL FREE DNA; CISPLATIN; DNA; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; TUMOR MARKER;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; DNA EXTRACTION; FEMALE; FLUOROMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; TREATMENT RESPONSE; ADENOCARCINOMA; AGED; BLOOD; CANCER STAGING; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; LUNG NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA; DNA, NEOPLASM; FEMALE; FLUOROMETRY; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS;

EID: 84949058124     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.00676-2015     Document Type: Article

References (30)

1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386.
2. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e1S-e29S.
3. Ost DE, Yeung SC, Tanoue LT, et al. Clinical and organizational factors in the initial evaluation of patients with lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e121S-e141S.
4. Nana-Sinkam SP, Powell CA. Molecular biology of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143: e30S-e39S.
5. Peters S, Adjei AA, Gridelli C, et al. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: Suppl. 7, 56-64.
6. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247.
7. Ulivi P, Silvestrini R. Role of quantitative and qualitative characteristics of free circulating DNA in the management of patients with non-small cell lung cancer. Cell Oncol 2013; 36: 439-448.
8. Schwarzenbach H, Hoon DS, Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
9. Jung K, Fleischhacker M, Rabien A. Cell-free DNA in the blood as a solid tumor biomarker: a critical appraisal of the literature. Clin Chim Acta 2010; 411: 1611-1624.
10. Couraud S, Vaca-Paniagua F, Villar S, et al. Noninvasive diagnosis of actionable mutations by deep sequencing of circulating free DNA in lung cancer from never-smokers: a proof-of-concept study from BioCAST/IFCT-1002. Clin Cancer Res 2014; 20: 4613-4624.
11. Sozzi G, Conte D, Mariani L, et al. Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients. Cancer Res 2001; 61: 4675-4678.
12. Leon SA, Shapiro B, Sklaroff DM, et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977; 37: 646-650.
13. Gautschi O, Bigosch C, Huegli B, et al. Circulating deoxyribonucleic acid as prognostic marker in non-small-cell lung cancer patients undergoing chemotherapy. J Clin Oncol 2004; 22: 4157-4164.
14. Lee YJ, Yoon KA, Han JY, et al. Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. Clin Cancer Res 2011; 17: 5179-5187.
15. Kumar S, Guleria R, Singh V, et al. Plasma DNA level in predicting therapeutic efficacy in advanced nonsmall cell lung cancer. Eur Respir J 2010; 36: 885-892.
16. Toffart AC, Timsit JF, Couraud S, et al. Immunohistochemistry evaluation of biomarker expression in non-small cell lung cancer (Pharmacogenoscan study). Lung Cancer 2014; 83: 182-188.
17. Toffart AC, Moro-Sibilot D, Couraud S, et al. Evaluation of RECIST in chemotherapy-treated lung cancer: the Pharmacogenoscan Study. BMC Cancer 2014; 14: 989.
18. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5: 649-655.
19. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th Edn. New York, Springer, 2009.
20. Newman AM, Bratman SV, To J, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20: 548-554.
21. Beau-Faller M, Gaub MP, Schneider A, et al. Plasma DNA microsatellite panel as sensitive and tumor-specific marker in lung cancer patients. Int J Cancer 2003; 105: 361-370.
22. van der Drift MA, Hol BE, Klaassen CH, et al. Circulating DNA is a non-invasive prognostic factor for survival in non-small cell lung cancer. Lung Cancer 2010; 68: 283-287.
23. Fournié GJ, Courtin JP, Laval F, et al. Plasma DNA as a marker of cancerous cell death: investigations in patients suffering from lung cancer and in nude mice bearing human tumours. Cancer Lett 1995; 91: 221-227.
24. Sirera R, Bremnes RM, Cabrera A, et al. Circulating DNA is a useful prognostic factor in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011; 6: 286-290.
25. Sozzi G, Roz L, Conte D, et al. Plasma DNA quantification in lung cancer computed tomography screening: five-year results of a prospective study. Am J Respir Crit Care Med 2009; 179: 69-74.
26. Marcq M, Vallée A, Bizieux A, et al. Detection of EGFR mutations in the plasma of patients with lung adenocarcinoma for real-time monitoring of therapeutic response to tyrosine kinase inhibitors? J Thorac Oncol 2014; 9: e49-e50.
27. Szpechcinski A, Struniawska R, Zaleska J, et al. Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. J Physiol Pharmacol 2008; 59: 675-681.
28. Gormally E, Caboux E, Vineis P, et al. Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 2007; 635: 105-117.
29. Qiu M, Wang J, Xu Y, et al. Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2015; 24: 206-212.
30. Oxnard GR, Paweletz CP, Kuang Y, et al. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res 2014; 20: 1698-1705.